Utah Medical Products(UTMD) - 2024 Q4 - Annual Results

Financial Performance - Revenues for 2024 decreased by 19% to $40.9 million compared to$ 50.2 million in 2023[4] - Net Income for 2024 was $9.2 million, a decline of 17% from$ 11.1 million in 2023[4] - Earnings Per Share (EPS) fell by 13% to $1.73 in 2024 from$ 1.99 in 2023[2] - In Q4 2024, total revenues were $9.2 million, down 25.8% from$ 12.3 million in Q4 2023[11] - The decline in annual revenues was primarily due to a $5.9 million (69%) drop in OEM sales to PendoTECH[17] - OUS distributor sales, excluding Filshie devices, decreased by$ 2.1 million (20%) in 2024[17] - Gross Profit (GP) for 2024 was $5,895 lower (19.6%) than in 2023, with a GP margin of 59.0% compared to 59.8% in 2023[24] - Operating Income (OI) decreased by$ 3,183 (19.0%) to $13,594 in 2024 compared to$ 16,777 in 2023[25] - Consolidated 2024 EBT was $16,802, representing 41.1% of sales, down from$ 20,089 (40.0% of sales) in 2023[33] - Adjusted consolidated EBITDA for 2024 was $19,852, a decrease from$ 26,635 in 2023, with a percentage of sales at 48.5% compared to 53.0% in 2023[35][36] - UTMD's non-US GAAP adjusted consolidated EBITDA for 2024 was $19,852 million, down 25.7% from$ 26,635 million in 2023[37] - Net Income for 2024 was $13,874 million, a decrease of 16.6% compared to$ 16,635 million in 2023, representing 33.9% of sales[38] - Diluted EPS for 2024 was $3.961, down 13.4% from$ 4.574 in 2023, with diluted shares decreasing from 3,637,071 to 3,503,165[39] Sales and Revenue Trends - The company expects a slight increase in sales from its China distributor for blood pressure monitoring kits in 2025[17] - UTMD projects higher OUS Filshie device sales in 2025 due to expected regulatory approvals[17] - OUS USD-denominated sales in 2024 were $17,458, a decrease of$ 4,562 (20.7%) compared to $22,020 in 2023[18] - Domestic U.S. sales in 2024 were$ 23,444, down $4,759 (16.9%) from$ 28,204 in 2023[21] - Sales invoiced in foreign currencies were $12,911, representing 74% of OUS sales and 32% of total consolidated sales[19] - The combined weighted-average favorable FX impact on 2024 foreign currency OUS sales was 0.3%, increasing reported USD sales by$ 113 compared to 2023[20] Shareholder Actions and Stock Performance - UTMD repurchased over 8% of its shares during the year, contributing to a stock price decline of 27%[2] - UTMD repurchased a total of 301,961 shares in 2024 at an average cost of $66.13 per share, totaling$ 19.968 million[44] - The number of outstanding shares at the end of 2024 was 3,335,156, down 8.1% from 3,629,525 at the end of 2023[40] - Dividends paid in 2024 totaled $4,260 million ($ 1.20 per share), slightly lower than $4,282 million ($ 1.18 per share) in 2023[43] Liquidity and Assets - Total cash and investments at the end of 2024 were $82.976 million, a decrease of$ 9.9 million from $92.868 million at the end of 2023[45] - The company's total assets decreased to$ 122.538 million at the end of 2024 from $135.458 million at the end of 2023[50] - The current ratio as of December 31, 2024, was 25.6, indicating strong liquidity[48] - The average inventory turns in 2024 were 1.8, reflecting inventory management efficiency[48] Future Outlook - Looking forward to 2025, UTMD expects total WW consolidated revenues to be lower again, in the low to mid-single percentage digits relative to 2024[23] - Litigation expenses in 2024 were$ 2,139 (5.2% of sales), up from $1,660 (3.3% of sales) in 2023[30]